Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Inhibrx Biosciences rises on early clinical success; Ozekibart shows promise in colorectal cancer. Read here for an analysis ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

AEMD READ THE FULL AEMD RESEARCH REPORT Data Safety Monitoring Board Recommends Progressing Trial Without Modification Aethlon Medical’s (NASDAQ:AEMD) current primary focus is on researching lead ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, explains how E7386 and lenvatinib work together to ...

Key Points Pfizer’s earnings and stock price soared in early pandemic days thanks to its coronavirus treatment and ...

Aethlon Medical announces DSMB completes its scheduled safety review and recommended advancing to the next patient cohort without modification: San Diego Thursday, July 17, 2025, ...

Dr. Ma discussed key findings that have been shared so far this year on the topic of evolving treatment strategies for ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...